Outcomes for olfactory neuroblastoma treated with induction chemotherapy

Su, Shirley Y.; Bell, Diana; Ferrarotto, Renata; Phan, Jack; Roberts, Dianna B.; Kupferman, Michael E.; Frank, Steven J.; Fuller, Clifton D.; Gunn, G. Brandon; Kies, Merrill S.; Glisson, Bonnie S.; Hanna, Ehab Y.

doi:10.1002/hed.24822

Cited by 71 publications

(64 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The characteristics of ONB and non‐ONB head and neck NSCCs can differ substantially . Accordingly, we compared clinical results between ONB ( n = 5) and non‐ONB ( n = 30).…”

Section: Resultsmentioning

confidence: 99%

“…The characteristics of ONB and non-ONB head and neck NSCCs can differ substantially. (12)(13)(14) Accordingly, we compared clinical results between ONB (n = 5) and non-ONB (n = 30). The 3-year local control rates for ONB and non-ONB were 100% and 92%, respectively (P = 0.41).…”

Section: Resultsmentioning

confidence: 99%

“…Our study included five patients with ONB, and their outcomes were excellent, with 3-year local control and OS rates of 100% and 100%, respectively, which are comparable to previous results of carbon-ion radiotherapy. (2) Olfactory neuroblastoma has been reported to be sensitive to chemotherapy, (13,18) due to different characteristics compared to other NSCCs, such as adenoid cystic carcinoma. Because of its distinct features, ONB should generally be distinguished from other forms of NSCCs.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Prospective observational study of carbon‐ion radiotherapy for non‐squamous cell carcinoma of the head and neck

et al. 2017

View full text Add to dashboard Cite

To evaluate the efficacy and safety of carbon‐ion radiotherapy for non‐squamous cell carcinoma of the head and neck, 35 patients were enrolled in this prospective study. The primary end‐point was the 3‐year local control rate, and the secondary end‐points included the 3‐year overall survival rate and adverse events. Acute and late adverse events were evaluated according to the Common Terminology Criteria for Adverse Events, version 4.0. The median follow‐up time for all patients was 39 months. Thirty‐two and three patients received 64.0 Gy (relative biological effectiveness) and 57.6 Gy (relative biological effectiveness) in 16 fractions, respectively. Adenoid cystic carcinoma was dominant (60%). Four patients had local recurrence and five patients died. The 3‐year local control and overall survival rates were 93% and 88%, respectively. Acute grade 2–3 radiation mucositis (65%) and dermatitis (31%) was common, which improved immediately with conservative therapy. Late mucositis of grade 2, grade 3, and grade 4 were observed in 11, one, and no patients, respectively. There were no adverse events of grade 5. Carbon‐ion radiotherapy achieved excellent local control and overall survival rates for non‐squamous cell carcinoma. However, the late mucosal adverse events were not rare, and meticulous treatment planning is required. Trial registration no. UMIN000007886.

show abstract

“…The characteristics of ONB and non‐ONB head and neck NSCCs can differ substantially . Accordingly, we compared clinical results between ONB ( n = 5) and non‐ONB ( n = 30).…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Prospective observational study of carbon‐ion radiotherapy for non‐squamous cell carcinoma of the head and neck

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In adults, chemotherapy is recommended in cases of high‐grade and positive margins tumors, unresectable tumors, metastatic disease, and relapses . Response rate to neoadjuvant chemotherapy is higher in a Hyams high‐grade group compared to a Hyams low‐grade group, 78% versus 50%, respectively . Furthermore, Polin et al showed that patients with a response to neoadjuvant therapy with chemotherapy and/or RT have a significant lower rate of disease‐related mortality .…”

Section: Discussionmentioning

confidence: 99%

“…[12][13][14][15][16] Chemotherapy might be used in case of high-grade, recurrent, or locoregionally advanced tumors. [17][18][19] In pediatric cases, chemotherapy combined with surgery and radiotherapy (RT) is often the treatment of choice in advanced diseases compared to adult ones. 3,6 The incidence of cervical node metastases is about 10% at diagnosis but can increase to 20% during the disease in adults.…”

mentioning

confidence: 99%

Pattern of loco‐regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (Fracture) contribution

Dumont

Fresneau

Claude

et al. 2020

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Background Esthesioneuroblastoma (ENB) is a rare neuroectodermal tumor that seldom occurs during childhood. Multimodal treatments are currently proposed, but the place of each therapy is still in debate. Our objective is to describe clinical evolution, especially the pattern of relapses and determine contributors to tumor progression. Procedure Medical charts of all children (≤18 years) affected by ENB treated in France from January 1990 to December 2015 were retrospectively analyzed. Results Eighteen patients were selected (10 males). Median age at diagnosis was 12.2 years (0.9‐18). Tumor extension was Kadish stage A (n = 1), B (n = 3), C (n = 10), and D (n = 4). Hyams histological grades were I (n = 1), II (n = 3), III (n = 6), and IV (n = 6) (in two cases not defined). Initial cervical nodal spread was assessed by magnetic resonance imaging (n = 15), computed tomography scan (n = 16), fluorodeoxyglucose‐positron emission tomography‐computed tomography (n = 7), and cytological/histological analysis (n = 2). N1 stage was confirmed by imaging in two of 18 cases and one of two cases had cervical node dissection with neck irradiation (58 Gy). After a median follow‐up of survivors of 7.6 years (3.8‐17.9), 10 patients developed neuromeningeal progression, whereas no cervical nodal relapse occurred and only eight survived. Both 5‐year overall and event‐free survival rates were 44.4% (±11.7%). Conclusions The poor prognosis is mainly related to neuromeningeal dissemination that should be considered during treatment strategy. However, cervical lymph node relapse is rare.

show abstract

Multicenter Survival Analysis and Application of an Olfactory Neuroblastoma Staging Modification Incorporating Hyams Grade

Choby

Geltzeiler

Almeida

et al. 2023

JAMA Otolaryngol Head Neck Surg

View full text Add to dashboard Cite

ImportanceCurrent olfactory neuroblastoma (ONB) staging systems inadequately delineate locally advanced tumors, do not incorporate tumor grade, and poorly estimate survival and recurrence.ObjectiveThe primary aims of this study were to (1) examine the clinical covariates associated with survival and recurrence of ONB in a modern-era multicenter cohort and (2) incorporate Hyams tumor grade into existing staging systems to assess its ability to estimate survival and recurrence.Design, Setting, and ParticipantsThis retrospective, multicenter, case-control study included patients with ONB who underwent treatment between January 1, 2005, and December 31, 2021, at 9 North American academic medical centers.InterventionStandard-of-care ONB treatment.Main Outcome and MeasuresThe main outcomes were overall survival (OS), disease-free survival (DFS), and disease-specific survival (DSS) as C statistics for model prediction.ResultsA total of 256 patients with ONB (mean [SD] age, 52.0 [15.6] years; 115 female [44.9%]; 141 male [55.1%]) were included. The 5-year rate for OS was 83.5% (95% CI, 78.3%-89.1%); for DFS, 70.8% (95% CI, 64.3%-78.0%); and for DSS, 94.1% (95% CI, 90.5%-97.8%). On multivariable analysis, age, American Joint Committee on Cancer (AJCC) stage, involvement of bilateral maxillary sinuses, and positive margins were associated with OS. Only AJCC stage was associated with DFS. Only N stage was associated with DSS. When assessing the ability of staging systems to estimate OS, the best-performing model was the novel modification of the Dulguerov system (C statistic, 0.66; 95% CI, 0.59-0.76), and the Kadish system performed most poorly (C statistic, 0.57; 95% CI, 0.50-0.63). Regarding estimation of DFS, the modified Kadish system performed most poorly (C statistic, 0.55; 95% CI, 0.51-0.66), while the novel modification of the AJCC system performed the best (C statistic, 0.70; 95% CI, 0.66-0.80). Regarding estimation of DSS, the modified Kadish system was the best-performing model (C statistic, 0.79; 95% CI, 0.70-0.94), and the unmodified Kadish performed the worst (C statistic, 0.56; 95% CI, 0.51-0.68). The ability for novel ONB staging systems to estimate disease progression across stages was also assessed. In the novel Kadish staging system, patients with stage VI disease were approximately 7 times as likely to experience disease progression as patients with stage I disease (hazard ratio [HR], 6.84; 95% CI, 1.60-29.20). Results were similar for the novel modified Kadish system (HR, 8.99; 95% CI, 1.62-49.85) and the novel Dulguerov system (HR, 6.86; 95% CI, 2.74-17.18).Conclusions and RelevanceThe study findings indicate that 5-year OS for ONB is favorable and that incorporation of Hyams grade into traditional ONB staging systems is associated with improved estimation of disease progression.

show abstract

Outcomes for olfactory neuroblastoma treated with induction chemotherapy

Abstract: ONB is a chemosensitive tumor and induction chemotherapy is an acceptable strategy for aggressive and locoregional advanced disease. Hyams grade may predict chemosensitivity and CR may be associated with improved survival.

Cited by 71 publications

References 32 publications

Prospective observational study of carbon‐ion radiotherapy for non‐squamous cell carcinoma of the head and neck

Prospective observational study of carbon‐ion radiotherapy for non‐squamous cell carcinoma of the head and neck

Pattern of loco‐regional relapses and treatment in pediatric esthesioneuroblastoma: The French very rare tumors group (Fracture) contribution

Multicenter Survival Analysis and Application of an Olfactory Neuroblastoma Staging Modification Incorporating Hyams Grade

Contact Info

Product

Resources

About